140 related articles for article (PubMed ID: 33099638)
1. Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
Palich R; Allavena C; Peytavin G; Soulie C; Tubiana R; Weiss L; Montoya Ferrer A; Duvivier C; Bouchaud O; Bottero J; Durand A; Lê MP; Marcelin AG; Dudoit Y; Assoumou L; Katlama C;
J Antimicrob Chemother; 2021 Jan; 76(2):477-481. PubMed ID: 33099638
[TBL] [Abstract][Full Text] [Related]
2. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
Katlama C; Assoumou L; Valantin MA; Soulié C; Martinez E; Béniguel L; Bouchaud O; Raffi F; Molina JM; Fellahi S; Peytavin G; Marcelin AG; Kolta S; Capeau J; Gibowski S; Cardon F; Reynes J; Costagliola D;
J Antimicrob Chemother; 2019 Sep; 74(9):2742-2751. PubMed ID: 31269208
[TBL] [Abstract][Full Text] [Related]
3. Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
Soulie C; Assoumou L; Abdi B; Sayon S; Nguyen T; Valantin MA; Beniguel L; Ferre V; Alloui C; Montes B; Avettand-Fenoel V; Delaugerre C; Descamps D; Martinez E; Reynes J; Peytavin G; Costagliola D; Katlama C; Calvez V; Marcelin AG;
J Antimicrob Chemother; 2020 Jul; 75(7):1943-1949. PubMed ID: 32259255
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.
Nyamankolly E; Bellecave P; Wittkop L; Le Marec F; Duffau P; Lazaro E; Vareil MO; Tumiotto C; Hessamfar M; Cazanave C; Perrier A; Leleux O; Bonnet F; Neau D
Int J Antimicrob Agents; 2023 Jan; 61(1):106696. PubMed ID: 36470511
[TBL] [Abstract][Full Text] [Related]
5. Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
Charpentier C; Fagard C; Colin C; Katlama C; Molina JM; Jacomet C; Visseaux B; Taburet AM; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
PLoS One; 2013; 8(1):e53621. PubMed ID: 23349724
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study.
Valantin MA; Durand L; Wirden M; Assoumou L; Caby F; Soulié C; Nguyen TT; Tubiana R; Kirstetter M; Junot H; Marcelin AG; Peytavin G; Tilleul P; Katlama C
J Antimicrob Chemother; 2019 Sep; 74(9):2716-2722. PubMed ID: 31273376
[TBL] [Abstract][Full Text] [Related]
7. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
8. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
Lê MP; Valantin MA; Assoumou L; Soulie C; Le Mestre S; Weiss L; Yazdanpanah Y; Molina JM; Bouchaud O; Raffi F; Reynes J; Calvez V; Marcelin AG; Costagliola D; Katlama C; Peytavin G;
Pharmacotherapy; 2019 Apr; 39(4):514-520. PubMed ID: 30815916
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
[TBL] [Abstract][Full Text] [Related]
10. Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.
Palich R; Abdi B; Wirden M; Lourida G; Tubiana R; Faycal A; Valantin MA; Schneider L; Seang S; Agher R; Simon A; Soulie C; Le MP; Peytavin G; Calvez V; Marcelin AG; Katlama C
J Antimicrob Chemother; 2021 Jun; 76(7):1893-1897. PubMed ID: 33855355
[TBL] [Abstract][Full Text] [Related]
11. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
Taiwo B; Murphy RL; Katlama C
Drugs; 2010 Sep; 70(13):1629-42. PubMed ID: 20731472
[TBL] [Abstract][Full Text] [Related]
12. Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
Schneider L; Ktorza N; Fourati S; Assoumou L; Courbon E; Caby F; Blanc C; Tindel M; Agher R; Marcelin AG; Calvez V; Peytavin G; Katlama C
HIV Clin Trials; 2012; 13(5):284-8. PubMed ID: 23134629
[TBL] [Abstract][Full Text] [Related]
13. Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients.
Calza L; Magistrelli E; Colangeli V; Manfredi R; Borderi M; Rossi N; Conti M; Mancini R; Viale P
AIDS Res Hum Retroviruses; 2017 Jul; 33(7):632-638. PubMed ID: 28088884
[TBL] [Abstract][Full Text] [Related]
14. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
[TBL] [Abstract][Full Text] [Related]
15. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
Ruane PJ; Brinson C; Ramgopal M; Ryan R; Coate B; Cho M; Kakuda TN; Anderson D;
HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
[TBL] [Abstract][Full Text] [Related]
16. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
[TBL] [Abstract][Full Text] [Related]
17. Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).
Soulié C; Assoumou L; Darty M; Rodriguez C; Donati F; Sayon S; Peytavin G; Valantin MA; Caby F; Schneider L; Canestri A; Costagliola D; Katlama C; Calvez V; Marcelin AG;
J Antimicrob Chemother; 2015 Dec; 70(12):3339-44. PubMed ID: 26396157
[TBL] [Abstract][Full Text] [Related]
18. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.
Monteiro P; Perez I; Laguno M; Martínez-Rebollar M; González-Cordon A; Lonca M; Mallolas J; Blanco JL; Gatell JM; Martínez E
J Antimicrob Chemother; 2014 Mar; 69(3):742-8. PubMed ID: 24128667
[TBL] [Abstract][Full Text] [Related]
19. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.
Calin R; Paris L; Simon A; Peytavin G; Wirden M; Schneider L; Valantin MA; Tubiana R; Agher R; Katlama C
Antivir Ther; 2012; 17(8):1601-4. PubMed ID: 22941896
[TBL] [Abstract][Full Text] [Related]
20. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM;
Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
